Table 2. Cox PH model of overall survival for baseline markers in patients with androgen-dependent disease and skeletal metastases, and castrate-resistant disease and skeletal metastases.
|
Androgen-dependent disease and skeletal metastases
|
Castrate-resistant disease and skeletal metastases
|
|||
|---|---|---|---|---|
| Variable | HR (95% CI) | P -value | HR (95% CI) | P -value |
| Baseline number of lesions | 1.02 (1.0, 1.04) | 0.06 | 1.01 (0.99, 1.04) | 0.17 |
| Baseline logPSA | 1 (0.83, 1.2) | 0.99 | 1.22 (1.04, 1.43) | 0.01 |
| Baseline loguNTx | 1.47 (0.95, 2.26) | 0.08 | 1.62 (1.15, 2.29) | 0.01 |
| Baseline logBAP | 1.46 (1.05, 2.04) | 0.03 | 1.46 (1.11, 1.91) | 0.01 |
| Baseline BAP/uNTx | 2.09 (1.01, 4.34) | 0.05 | 1.12 (0.81, 1.55) | 0.49 |
Abbreviations: BAP=bone-specific alkaline phosphatase; CI=confidence interval; HR=hazard ratio; PSA=prostate-specific antigen; uNTx=urine N-telopeptide.